Skip to main content
SpringerLink
Log in

Peyronie’s Disease and Its Medical Management

  • Chapter
Male Infertility and Sexual Dysfunction

Abstract

Plastic induration of the penis, referred to as Peyronie’s disease, was described in 1743 by the French physician François de la Peyronie1 when he reported on three patients with scar tissue that resulted in an upward curvature of the penis during erection. This fibrous inelastic scar involving the tunica albuginea of the corpora cavernosa is the distinguishing characteristic of this disease. The typical symptoms include a palpable scar (frequently referred to as a Peyronie’s plaque), on the shaft of the penis, complaints of pain and abnormal curvature during erection, and difficulty with coitus because of the deformity or diminished rigidity or both. This condition often leads to unsatisfactory sexual performance and profound psychological trauma.2

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. de La Peyronie F. Sur quelques obstacles qui s’opposent a l’éjaculation naturelle de la 19. semence. Mem de l’Acad Roy de Chir 1743; 1:425–434.

    Google Scholar 

  2. Gelbard MK, Dorey F, James K. The natural 20. history of Peyronie’s disease. J Urol 1990; 144:1376–1379. 21.

    Google Scholar 

  3. Lindsay MB, Schain DM, Grambsch P, et al. The incidence of Peyronie’s disease in Rochester, Minnesota, 1950 through 1984. J Urol 1991; 146:1007–1009.

    PubMed  CAS  Google Scholar 

  4. Vorstman B, Lockhart J. Peyronie’s disease. 22. Probl Urol 1987; 1:507.

    Google Scholar 

  5. Hinman F. Etiologic factors in Peyronie’s dis- 23. ease. Urol Int 1980; 35:407–413.

    Article  PubMed  Google Scholar 

  6. Mira JG. Is it worthwhile to treat Peyronie’s disease. Urology 1980; 16:1–6. 24.

    Google Scholar 

  7. Williams JL, Thomas GG. The natural history of Peyronie’s disease. J Urol 1970; 103:75–76.

    PubMed  CAS  Google Scholar 

  8. Smith BH. Peyronie’s disease. Am J Clin Pathol 25. 1966; 45:670–678.

    Google Scholar 

  9. Somers KD, Sismour EN, Wright GL, et al. Isolation and characterization of collagen in 26. Peyronie’s disease. J Urol 1989; 141:629–631.

    PubMed  CAS  Google Scholar 

  10. Helvie WW, Ochsner SF. Radiation therapy in Peyronie’s disease. South Med J 1972; 65:1192–1196.

    Article  PubMed  CAS  Google Scholar 

  11. Blandy JP. Penis and scrotum. In: John Blandy, 27. ed. Urology, vol. 2. Oxford: Blackwell; 1976: 1049–1095.

    Google Scholar 

  12. Roddy MT, Goldstein I. Peyronie’s disease. Part I. AUA Update Series 1991; 10.

    Google Scholar 

  13. Devine CJ, Sommers KD, Wright GL Jr, et al. A working model for the genesis of Peyronie’s dis- 29. ease derived from its pathobiology. J Urol 1988; 139(part 2):286A, abstract 495.

    Google Scholar 

  14. Iacono F, Barva S, De Rosa G, et al. Microstructural disorders of tunica albuginea in patients affected by Peyronie’s disease with or without erection dysfunction. J Urol 1993; 150:1806–1809.

    PubMed  CAS  Google Scholar 

  15. Akkus E, Carrier S, Rahman J, et al. Structural alterations in the tunica albuginea: relevance to Peyronie’s disease and impotence. Int J Impotence 1994; Res 6(suppl 1):D206.

    Google Scholar 

  16. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol 1994; 151:1522–1524.

    PubMed  CAS  Google Scholar 

  17. Gelbard M. Peyronie’s disease. In: Hashmat AI, Das S, eds. The Penis. Malvern: Lea & Febiger; 1993:244–625.

    Google Scholar 

  18. Furlow WL, Swenson HE, Lee RE. Peyronie’s disease: a study of its natural history and treatment with orthovoltage radiotherapy. J Urol 1975; 114:69–71.

    PubMed  CAS  Google Scholar 

  19. Williams G, Green NA. The nonsurgical treatment of Peyronie’s disease. Br J Urol 1980; 52:392–395.

    Article  PubMed  CAS  Google Scholar 

  20. Mazo VE. Nov metod za lschenie na bolestta na Peironi. Khirurgiia (Sofia) 1989; 42(4):30–31.

    CAS  Google Scholar 

  21. Bellorofonte C, Ruoppolo M, Tura M, et al. Possibilita di impiego del litotritore piezoelettrico nel trattamento delle fibrosi cavernose gravi. Arch Ital Urol Netrol Androl 1989; 61: 417–422.

    CAS  Google Scholar 

  22. Frank IN, Scott WW. The ultrasonic treatment of Peyronie’s diesease. J Urol 1971; 106:83–87.

    PubMed  CAS  Google Scholar 

  23. Scott WW, Scardino PL. A new concept in the treatment of Peyronie’s disease. South Med J 1948; 41:173–177.

    Article  PubMed  CAS  Google Scholar 

  24. Zarafonetis CJD, Horrax TM. Treatment of Peyronie’s disease with Potaba. J Urol 1959; 81:770–772.

    PubMed  CAS  Google Scholar 

  25. Ralph DJ, Brooks MD, Battazzo GF, et al. The treatment of Peyronie’s disease with tamoxifen. Br J Urol 1992; 70:648–651.

    Article  PubMed  CAS  Google Scholar 

  26. Colletta AA, Wakefield LM, Howell FV, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62:405–409.

    Article  PubMed  CAS  Google Scholar 

  27. Wahl SM, McCartney-Francis N, Mergenhagen SE. Inflammatory and immunomodulatory roles of TGF-(3. Immunol Today 1989; 10:258–261.

    Article  PubMed  CAS  Google Scholar 

  28. Oosterlinck W, Renders G. Treatment of Peyronie’s disease with procarbazine Br J Urol 1975; 47:219–220.

    Article  PubMed  CAS  Google Scholar 

  29. Morgan RI, Pryor JP. Procarbazine (Natulan) in the treatment of Peyronie’s disease. Br J Urol 1978; 50:111–113.

    Article  PubMed  CAS  Google Scholar 

  30. Akkus E, Carrier S, Rehman J, et al. Is colchicine effective in Peyronie’s disease? A pilot study. Urology 1994; 44:291–295.

    Article  PubMed  CAS  Google Scholar 

  31. Kershenobich D, Vargas F, Garsia-Tsao G, et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 1988; 318:1709–1713.

    Article  PubMed  CAS  Google Scholar 

  32. Diegelmann RF, Peterkofsky B. Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc Natl Acad Sci USA 1972; 69:892–896.

    Article  PubMed  CAS  Google Scholar 

  33. Ehrlich HP, Bornstein P. Microtubules in transcellular movement of procollagen. Nature 1972; 238:257–260.

    CAS  Google Scholar 

  34. Harris ED Jr, Krane SM. Effects of colchicine on collagenase in culture of rheumatoid synovium. Arthritis Rheum 1971; 14:669–684.

    Article  PubMed  CAS  Google Scholar 

  35. Tearsley GH. Peyronie’s disease: the new approach. J Urol 1954; 105:523.

    Google Scholar 

  36. Bodner H, Howard AH, Kaplan JH. Peyronie’s disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol 1954; 134:400.

    Google Scholar 

  37. Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol 1954; 72:400–403.

    Google Scholar 

  38. Pentland AP, Anderson TF. Plantar fibromatosis responds to intralesional steroids. J Am Acad Dermatol 1985; 2:212–214.

    Article  Google Scholar 

  39. Uitto J, Santa-Cruz DJ, Eisen AZ, et al. Chromomycosis. Successful treatment with 5fluorocytosine. J Cutan Pathol 1979; 6:77–84.

    Article  PubMed  CAS  Google Scholar 

  40. Morales A, Bruce AW. The treatment of Peyronie’s disease with parathyroid hormone. J Urol 1975; 114:901–902.

    PubMed  CAS  Google Scholar 

  41. Walker DG, Lapiere CM, Gross J. A collagenolytic factor in rat bone promoted by parathyroid extract. Biochem Biophys Res Commun 1964; 15:397.

    CAS  Google Scholar 

  42. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res 1982; 10:135–140.

    Article  PubMed  CAS  Google Scholar 

  43. Gelbard MK, James N, Riach P, et al. Collagenase versus placebo in the treatment of Peyronie’s disease: a double blind study. J Urol 1993; 149:397–402.

    Google Scholar 

  44. Kelâmi A. Classification of congenital and acquired penile deviation. Urol Int 1983; 38:229–233.

    Google Scholar 

  45. Gustafson H, Johansson B, Edsmyr F. Peyronie’s disease: experience of local treatment with Orgotein. Eur Urol 1981; 7:346–348.

    PubMed  CAS  Google Scholar 

  46. Bartsch C, Menander-Huber KB, Huber W, et al. Orgotein, a new drug for the treatment of Peyronie’s disease. Eur J Rheumatol Inflamm 1981; 4:250–259.

    PubMed  CAS  Google Scholar 

  47. Verges J, Chateau A. Nouveau traitement dela maladie La Peyronie: la superoxyde desmutase par ionisations. Comparaison avec une serie ancienne classique. Ann Urol (Paris) 1988; 22:143–144.

    CAS  Google Scholar 

  48. Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie’s) disease. Int Urol Nephrol 1993; 25:169–172.

    PubMed  CAS  Google Scholar 

  49. Kelly RB. Pathways of protein secretion in eukariots. Science 1985; 230:25–32.

    Article  PubMed  CAS  Google Scholar 

  50. Aggeler J, Frisch SM, Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J Cell Biol 1984; 98:1662–1671.

    Article  PubMed  CAS  Google Scholar 

  51. Gelbard M, Lindler A, Chvapil M, et al. Topical beta-aminopropionitrile in the treatment of Peyronie’s disease. J Urol 1983; 129:746–748.

    PubMed  CAS  Google Scholar 

  52. Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie’s disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25:89–94.

    Article  PubMed  CAS  Google Scholar 

  53. Berman R, Duncan MR. Short-term keloid treatment in vivo with human interferon alpha2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan and collagenase production in vitro. J Am Acad Dermatol 1989; 21:694–702.

    Article  PubMed  CAS  Google Scholar 

  54. Duncan MR, Berman B. Persistence of a reduced-collagen producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 1987; 79:1318–1324.

    Article  PubMed  CAS  Google Scholar 

  55. Kahari V-M, Heino J, Vuorio T, et al. Interferon-alpha and interferon-gamma reduce excessive collagen synthesis and procollagen mRNA levels of scleroderma fibroblasts in culture. Biochem Biophys Acta 1988; 968:45–50.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Laurance A. Levine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lev Elterman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Andrology and Male Infertility Department of Urology, Tulane University School of Medicine, 1430 Tulane Avenue SL 42, 70112-2699, New Orleans, LA, USA

    Wayne J. G. Hellstrom (Associate Professor Urology, Chief) (Associate Professor Urology, Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Levine, L.A., Elterman, L. (1997). Peyronie’s Disease and Its Medical Management. In: Hellstrom, W.J.G. (eds) Male Infertility and Sexual Dysfunction. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1848-7_35

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1848-7_35

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7310-3

  • Online ISBN: 978-1-4612-1848-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation